Healthsens Prostasens®: one step ahead of prostate cancer
Development and validation of a POCT (Point of Care Testing) device for an early diagnosis of prostate cancer.
Currently, Healthsens is developing an exclusive immunological Point of Care Testing (POCT) device that will allow early and non-invasive diagnosis of prostate cancer. Healthsens Prostasens® is a biotechnological innovation able to calculate the Prostate Health Index (PHI), which will allow patients to monitor their disease, changing the lives of millions of people.
Healthsens is developing Prostasens® a portable and low-cost Point of Care Testing (POCT) device that will quantify, using a single drop of serum, three biomarkers associated to prostate cancer. The final device will be an electrochemical sensor, composed of three electrodes, that will allow the simultaneous and exact determination of total PSA, free PSA and [-2]proPSA.
Unlike the methodologies most commonly used in clinical practice, Healthsens Prostasens® will allow, in a simple and non-invasive way, to obtain global information about the chance of patients developing prostate cancer, not limited to providing an isolated concentration value, but will also calculate the Prostate Health Index (PHI).
The PHI, calculated from the serum concentrations of total PSA, free PSA and [-2]proPSA, is a multivariable index that indicates the presence of a tumor, its state of progrsssion and its agresiveness. The use of PHI is approved in Europe, USA (FDA) and Australia.
Healthsens Prostasens® commercialization is intended to ease the prompt diagnosis of prostate cancer, making it accesible to patients. Healthsens Prostasens® would facilitate a simple and rapid population screening program, without need of neither digital rectal examination nor biopsies and at a reduced-price.
Prostate cancer is the most common type of cancer among male population, increasing its incidence and mortality with age. Approximately 1 in 8 men will be diagnosed with prostate cancer over the course of their lives.
According to data from the Spanish Association of Urology (AEU), one and a half million Spanish males, aged between 50 and 75, are at risk of suffering from prostate cancer.
Prostate cancer is the third leading cause of cancer death in males. Globally, 2.8% of all deaths among the male population are due to this desease. Annually in Spain there are 3,600 deaths due to this pathology.